{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:22:08Z","timestamp":1774981328235,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pupt.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,5,11]],"date-time":"2014-05-11T01:45:36Z","timestamp":1399772736000},"page":"119-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Antibiotic prophylaxis in COPD: Why, when, and for whom?"],"prefix":"10.1016","volume":"32","author":[{"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2014.05.002_bib1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60968-9","article-title":"Chronic obstructive pulmonary disease","volume":"379","author":"Decramer","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2014.05.002_bib2","doi-asserted-by":"crossref","unstructured":"Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Rev;CD004105. Published online: 21 Jan 2009. DOI: 10.1002\/14651858.","DOI":"10.1002\/14651858"},{"key":"10.1016\/j.pupt.2014.05.002_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/thoraxjnl-2012-201924","article-title":"Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD","volume":"67","author":"Garcha","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2014.05.002_bib6","first-page":"219","article-title":"Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease","volume":"169","author":"Singh","year":"2009","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pupt.2014.05.002_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1183\/09031936.00118912","article-title":"Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice","volume":"41","author":"Miravitlles","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.05.002_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.rmed.2012.10.024","article-title":"Chronic bronchial infection in COPD. Is there an infective phenotype?","volume":"107","author":"Matkovic","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib10","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1056\/NEJMra0800353","article-title":"Infection in the pathogenesis and course of chronic obstructive pulmonary disease","volume":"359","author":"Sethi","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1465-9921-11-58","article-title":"Colour of sputum is a marker of bacterial colonization in COPD","volume":"11","author":"Miravitlles","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.pupt.2014.05.002_bib12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1164\/rccm.200210-1179OC","article-title":"Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease","volume":"167","author":"Wilkinson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1183\/09031936.00081409","article-title":"Infection as a comorbidity of COPD","volume":"35","author":"Sethi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.05.002_bib14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1183\/09031936.00208011","article-title":"Macrolide effects on the prevention of COPD exacerbations","volume":"40","author":"Yamaya","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.05.002_bib15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1378\/chest.120.3.730","article-title":"Erythromycin and common cold in COPD","volume":"120","author":"Suzuki","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.05.002_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pupt.2009.12.002","article-title":"Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy","volume":"23","author":"Blasi","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.05.002_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000321374","article-title":"Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease","volume":"80","author":"He","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2014.05.002_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/COPD.S23655","article-title":"Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations","volume":"6","author":"Pomares","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.pupt.2014.05.002_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","article-title":"Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Sethi","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.pupt.2014.05.002_bib22","first-page":"379","article-title":"studio prospective y comparative (1994\u20131998) sobre la influencia del tratamiento corto profil\u00e1ctico con azitromicina en pacientes con EPOC evolucionada","volume":"13","author":"G\u00f3mez","year":"2000","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.pupt.2014.05.002_bib23","doi-asserted-by":"crossref","first-page":"e004140","DOI":"10.1136\/bmjopen-2013-004140","article-title":"Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations","volume":"3","author":"O\u2019Reilly","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.pupt.2014.05.002_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/thoraxjnl-2013-204089","article-title":"Response to: should we give long-term macrolide therapy for COPD?","volume":"68","author":"Albert","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2014.05.002_bib26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl.\u00a0F","key":"10.1016\/j.pupt.2014.05.002_bib27","first-page":"41","article-title":"Clinical safety profile of newer fluoroquinolones","volume":"16","author":"Rodvold","year":"1999","journal-title":"Infect Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib28","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1378\/chest.128.5.3398","article-title":"A\u00a0randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community- acquired pneumonia","volume":"128","author":"Morganroth","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.05.002_bib29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1164\/rccm.201302-0289PP","article-title":"Antibiotics for acute and chronic obstructive pulmonary disease","volume":"188","author":"Miravitlles","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1378\/chest.12-1277","article-title":"Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial","volume":"143","author":"Rabe","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.05.002_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.pupt.2014.05.002_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4104\/pcrj.2013.00074","article-title":"Long-term antibiotics in COPD: more benefit than harm?","volume":"22","author":"Miravitlles","year":"2013","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.pupt.2014.05.002_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.05.002_bib35","first-page":"497","article-title":"Use of antibiotics in COPD exacerbations: from treatment to prevention","volume":"67","author":"Wilson","year":"2013","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.pupt.2014.05.002_bib36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1378\/chest.10-1758","article-title":"Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients","volume":"140","author":"Mart\u00ednez-Garc\u00eda","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.05.002_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1164\/rccm.200305-648OC","article-title":"Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Patel","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/thorax.55.8.635","article-title":"Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care","volume":"55","author":"O\u2019Brien","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2014.05.002_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000331224","article-title":"Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease","volume":"84","author":"Almagro","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2014.05.002_bib40","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.rmed.2009.12.010","article-title":"Prognosis of COPD patients requiring frequent hospitalization: role of airway infection","volume":"104","author":"Renom","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2014.05.002_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4104\/pcrj.2013.00061","article-title":"Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study","volume":"22","author":"James","year":"2013","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.pupt.2014.05.002_bib42","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s12325-008-0105-2","article-title":"Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation","volume":"25","author":"Dal Negro","year":"2008","journal-title":"Adv Ther"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T06:52:35Z","timestamp":1538635955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553914000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":42,"alternative-id":["S1094553914000509"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2014.05.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic prophylaxis in COPD: Why, when, and for whom?","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}